Open Access
Article
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer
Jeanny B Aragon-Ching1,Kirsten M Williams1,James L Gulley1
1
Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
DOI: 10.2741/2441 Volume 12 Issue 13, pp.4957-4971
Published: 01 September 2007
Abstract

Prostate cancer is the most common non-cutaneous malignancy in American men. Standard therapeutic strategies for systemic disease include androgen-deprivation therapy (ADT) and chemotherapy, both of which are palliative. However, there is a growing interest in the use of immunotherapy for prostate cancer. Evidence suggests that ADT may 1) enhance lymphopoiesis and thus potentially improve immune responses to vaccine, 2) renew thymopoiesis and thus reverse age-induced thymic involution, 3) augment B-cell development, and 4) mitigate tolerance to prostate cancer antigens. Although no vaccines are currently approved for prostate cancer, there are many promising agents under investigation. This review focuses on recent findings on immune regulation by androgens and immune-system regeneration with ADT, with emphasis on the rationale for the combination of ADT and vaccines in the clinical treatment of prostate cancer.

Share and Cite
Jeanny B Aragon-Ching, Kirsten M Williams, James L Gulley. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Frontiers in Bioscience-Landmark. 2007. 12(13); 4957-4971.